Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 May 1;140(5):486-494.
doi: 10.1001/jamaophthalmol.2022.0050.

Global Estimates of Diabetic Retinopathy Prevalence and Progression in Pregnant Women With Preexisting Diabetes: A Systematic Review and Meta-analysis

Felicia Widyaputri  1   2   3 , Sophie L Rogers  2 , Rathika Kandasamy  2 , Alexis Shub  4   5 , Robert C A Symons  1   2   6 , Lyndell L Lim  1   2   7
Affiliations
Meta-Analysis

Global Estimates of Diabetic Retinopathy Prevalence and Progression in Pregnant Women With Preexisting Diabetes: A Systematic Review and Meta-analysis

Felicia Widyaputri et al. JAMA Ophthalmol. .

Abstract

Importance: Diabetic retinopathy (DR) may be worsened by pregnancy in pregnant women with preexisting type 1 diabetes (T1D) or type 2 diabetes (T2D). Conflicting findings from previous studies have resulted in inconsistencies in guidelines regarding DR management in pregnancy. Global estimates of DR prevalence and progression in pregnancy are therefore required to provide clearer information about the overall true burden of DR in this population.

Objective: To estimate the prevalence of DR and its progression rate in pregnant women with preexisting T1D or T2D diagnosed before pregnancy.

Data sources: For this systematic review and meta-analysis, conducted from November 27, 2018, to June 29, 2021, a systematic literature search was conducted in MEDLINE/Ovid, Embase/Ovid, and Scopus databases to identify English-language articles that were published from inception through October 2020.

Study selection: Observational studies that reported on DR and its changes in pregnant women with preexisting T1D and T2D.

Data extraction and synthesis: Two independent reviewers extracted relevant data from each included study. Data were pooled using a random-effects model with the Freeman-Tukey double arcsine transformation. This study followed the Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines.

Main outcomes and measures: Prevalence of any DR, proliferative DR (PDR), and DR progression rates.

Results: A total of 18 observational studies involving 1464 pregnant women with T1D and 262 pregnant women with T2D were included in the analysis. The pooled prevalence of any DR and PDR in early pregnancy was 52.3 (95% CI, 41.9-62.6) and 6.1 (95% CI, 3.1-9.8) per 100 pregnancies, respectively. The pooled progression rate per 100 pregnancies for new DR development was 15.0 (95% CI, 9.9-20.8), worsened nonproliferative DR was 31.0 (95% CI, 23.2-39.2), progression from nonproliferative DR to PDR was 6.3 (95% CI, 3.3-10.0), and worsened PDR was 37.0 (95% CI, 21.2-54.0). DR progression rates per 100 pregnancies were similar between the T1D and T2D groups, except for the development of new DR (T1D groups: 15.8; 95% CI, 10.5-21.9; T2D groups: 9.0; 95% CI, 4.9-14.8). A global trend toward a lower DR progression rate was observed after the 1989 St Vincent Declaration.

Conclusions and relevance: Results of this systematic review and meta-analysis suggest that women with T1D and T2D had a similar risk of DR progression during pregnancy. Despite improvements in the management of diabetes and diabetes during pregnancy, DR prevalence and progression in pregnant women with diabetes remains higher than the nonpregnant population with diabetes, highlighting the need to improve DR management in pregnancy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Widyaputri reported receiving a Ministry of Finance Scholarship from the Indonesian Endowment Fund for Education during the conduct of the study. Dr Lim reported receiving grants from Alfred Fenton Trust and Bayer and personal fees from Novartis, Novotech, and Allergan outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Pooled Progression Rate From None to Any Diabetic Retinopathy From Early Pregnancy to Around Delivery Using Studies With Similar Quality, by Diabetes Type
Weights are from random-effects analysis.
Figure 2.
Figure 2.. Pooled Progression Rate of Worsened Nonproliferative Diabetic Retinopathy (DR) by at Least 1 DR Level From Early Pregnancy to Around Delivery Using Studies With Similar Quality, by Diabetes Type
Weights are from random-effects analysis. NA indicates not applicable owing to insufficient included studies in this subgroup for this outcome.
Figure 3.
Figure 3.. Pooled Sight-Threatening Progression Rate From Nonproliferative Diabetic Retinopathy to Proliferative Diabetic Retinopathy From Early Pregnancy to Around Delivery Using Studies With Similar Quality, by Diabetes Type
Weights are from random-effects analysis. NA indicates not applicable owing to insufficient included studies in this subgroup for this outcome.
Figure 4.
Figure 4.. Pooled Sight-Threatening Progression Rate of Worsened Proliferative Diabetic Retinopathy From Early Pregnancy to Around Delivery Using Studies With Similar Quality, by Diabetes Type
Weights are from random-effects analysis.
See this image and copyright information in PMC

Comment in

References

    1. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14(4):179-183. doi:10.1080/09286580701396720 - DOI - PubMed
    1. Flaxman SR, Bourne RRA, Resnikoff S, et al. ; Vision Loss Expert Group of the Global Burden of Disease Study . Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(12):e1221-e1234. doi:10.1016/S2214-109X(17)30393-5 - DOI - PubMed
    1. Morrison JL, Hodgson LA, Lim LL, Al-Qureshi S. Diabetic retinopathy in pregnancy: a review. Clin Exp Ophthalmol. 2016;44(4):321-334. doi:10.1111/ceo.12760 - DOI - PubMed
    1. Diabetes Control and Complications Trial Research Group . Effect of pregnancy on microvascular complications in the diabetes control and complications trial. Diabetes Care. 2000;23(8):1084-1091. doi:10.2337/diacare.23.8.1084 - DOI - PMC - PubMed
    1. Diabetes care and research in Europe: the St Vincent Declaration. Diabet Med. 1990;7(4):360. doi:10.1111/j.1464-5491.1990.tb01405.x - DOI - PubMed

MeSH terms